The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer-Reference-Cited by-同舟云学术

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer

Published:2012-05 Issue:3 Volume:24 Page:272-277
ISSN:1040-8746
Container-title:Current Opinion in Oncology
language:en
Short-container-title:

Author:

Courtney Kevin D.,Taplin Mary-Ellen

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference36 articles.

1. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate.;Huggins;Cancer Res,1941

2. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland.;Huggins;Arch Surg,1941

3. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.;Ryan;J Clin Oncol,2010

4. 3rd, et al. The androgen axis in recurrent prostate cancer.;Mohler;Clin Cancer Res,2004

5. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.;Montgomery;Cancer Res,2008

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual targeting in prostate cancer with phytoconstituents as a potent lead: a computational approach for novel drug discovery;Journal of Biomolecular Structure and Dynamics;2023-08-30

2. The circHMGCS1-miR-205–5p-ErBB3 axis mediated the Sanggenon C-induced anti-proliferation effects on human prostate cancer;Pharmacological Research;2023-01

3. Treatment gains from the “sandwich method” of abiraterone acetate for men with metastatic prostate cancer: a case report and sharing of our experience;Translational Andrology and Urology;2020-06

4. Effect of N -methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide;Journal of Labelled Compounds and Radiopharmaceuticals;2017-05-30

5. BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients;Oncotarget;2016-01-09